1h Free Analyst Time
The publisher's latest Pharmaceutical and Healthcare disease pipeline guide Ankylosing Spondylitis (Bekhterev's Disease) - Drugs In Development, 2022, provides an overview of the Ankylosing Spondylitis (Bekhterev's Disease) (Musculoskeletal Disorders) pipeline landscape.Speak directly to the analyst to clarify any post sales queries you may have.
Ankylosing spondylitis is a type of arthritis that affects the spine. Ankylosing spondylitis symptoms include pain and stiffness from the neck down to the lower back. The spine's bones (vertebrae) may grow or fuse together, resulting in a rigid spine. These changes may be mild or severe, and may lead to a stooped-over posture.
Report Highlights
The publisher's Pharmaceutical and Healthcare latest pipeline guide Ankylosing Spondylitis (Bekhterev's Disease) - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Ankylosing Spondylitis (Bekhterev's Disease) (Musculoskeletal Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.The Ankylosing Spondylitis (Bekhterev's Disease) (Musculoskeletal Disorders) pipeline guide also reviews of key players involved in therapeutic development for Ankylosing Spondylitis (Bekhterev's Disease) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 4, 11, 11, 12, 1, 17, 10 and 1 respectively.
Ankylosing Spondylitis (Bekhterev's Disease) (Musculoskeletal Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Ankylosing Spondylitis (Bekhterev's Disease) (Musculoskeletal Disorders).
- The pipeline guide reviews pipeline therapeutics for Ankylosing Spondylitis (Bekhterev's Disease) (Musculoskeletal Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Ankylosing Spondylitis (Bekhterev's Disease) (Musculoskeletal Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Ankylosing Spondylitis (Bekhterev's Disease) (Musculoskeletal Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Ankylosing Spondylitis (Bekhterev's Disease) (Musculoskeletal Disorders)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Ankylosing Spondylitis (Bekhterev's Disease) (Musculoskeletal Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Ankylosing Spondylitis (Bekhterev's Disease) (Musculoskeletal Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
- Introduction
- Report Coverage
- Ankylosing Spondylitis (Bekhterev's Disease) - Overview
- Ankylosing Spondylitis (Bekhterev's Disease) - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Products under Development by Companies
- Ankylosing Spondylitis (Bekhterev's Disease) - Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Ankylosing Spondylitis (Bekhterev's Disease) - Companies Involved in Therapeutics Development
- Ankylosing Spondylitis (Bekhterev's Disease) - Drug Profiles
- Ankylosing Spondylitis (Bekhterev's Disease) - Dormant Projects
- Ankylosing Spondylitis (Bekhterev's Disease) - Discontinued Products
- Ankylosing Spondylitis (Bekhterev's Disease) - Product Development Milestones
- Featured News & Press Releases
- Aug 17, 2022: NICE Recommends RINVOQ (upadacitinib) as a treatment option for active ankylosing spondylitis (AS) in adults
- Jul 27, 2022: Mabpharm announces approval of clinical trial application of CMAB015 by the National Medical Products Administration of China
- Jul 21, 2022: Sandoz Supplemental Biologics License Application accepted by US FDA for biosimilar Hyrimoz (adalimumab-adaz) high concentration formulation (HCF)
- Jul 20, 2022: Health Canada approves AbbVie's RINVOQ® (upadacitinib) for the treatment of adults with active ankylosing spondylitis
- Jun 01, 2022: AbbVie Presents Positive Results from Phase 3 SELECT-AXIS 2 Trials of Upadacitinib (RINVOQ®) in Patients with Axial Spondyloarthritis at EULAR 2022
- May 02, 2022: FDA grants approval for AbbVie's Rinvoq to treat ankylosing spondylitis
- Apr 11, 2022: Celltrion Healthcare announces the availability of Yuflyma, a high-concentration, low-volume, citrate-free, and latex-free Humira (adalimumab) biosimilar in Canada
- Jan 20, 2022: Lynk doses first patient in Phase II ankylosing spondylitis drug trial
- Dec 28, 2021: Akeso's IL-17A monoclonal antibody (Gumokimab) completion of patient enrollment in phase II clinical trial for the treatment of ankylosing spondylitis
- Dec 08, 2021: Xinkanghe XKH004 ankylosing spondylitis phase II clinical trial investigator meeting was successfully held
- Oct 07, 2021: AbbVie's RINVOQ (upadacitinib) met primary and all ranked secondary endpoints in phase 3 study in ankylosing spondylitis
- Jun 25, 2021: AbbVie provides update regarding RINVOQ (upadacitinib) in psoriatic arthritis and ankylosing spondylitis in the U.S.
- Feb 16, 2021: Sandoz Canada completes its 5th biosimilar launch with new biosimilar Hyrimoz (adalimumab)
- Jan 25, 2021: European Commission approves AbbVie's RINVOQ (Upadacitinib) for the treatment of Psoriatic Arthritis and Ankylosing Spondylitis
- Dec 22, 2020: China IND application of recombinant anti-human IL-17A/F humanized monoclonal antibody injection for AS indication is accepted by CDE
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact the Publisher
- Disclaimer
- Number of Products under Development for Ankylosing Spondylitis (Bekhterev's Disease), 2022
- Number of Products under Development by Companies, 2022
- Products under Development by Companies, 2022
- Number of Products by Stage and Target, 2022
- Number of Products by Stage and Mechanism of Action, 2022
- Number of Products by Stage and Route of Administration, 2022
- Number of Products by Stage and Molecule Type, 2022
- Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by 3SBio Inc, 2022
- Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by AbbVie Inc, 2022
- Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Akeso Inc, 2022
- Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by AstraZeneca Plc, 2022
- Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Avesthagen Ltd, 2022
- Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Beijing Eastern Biotech Co Ltd, 2022
- Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Bio-Thera Solutions Ltd, 2022
- Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Biocad, 2022
- Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Biogen Inc, 2022
- Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Bioviz Technologies Pvt Ltd, 2022
- Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by BioXpress Therapeutics SA, 2022
- Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Boehringer Ingelheim International GmbH, 2022
- Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Bristol-Myers Squibb Co, 2022
- Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Celltrion Inc, 2022
- Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Clover Biopharmaceuticals Ltd, 2022
- Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by DNX Biopharmaceuticals Inc, 2022
- Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Dyadic International Inc, 2022
- Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Eli Lilly and Co, 2022
- Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Enzene Biosciences Ltd, 2022
- Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Foshan Rexie Biotechnology Co Ltd, 2022
- Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by FunPep Co Ltd, 2022
- Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Huabo Biopharm (Shanghai) Co Ltd, 2022
- Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Hualan Biological Engineering Inc, 2022
- Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Iltoo Pharma, 2022
- Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Immunwork Inc, 2022
- Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Izana Bioscience Ltd, 2022
- Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Jiangsu Carephar Pharmaceutical Co Ltd, 2022
- Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Jiangsu Hengrui Medicine Co Ltd, 2022
- Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by JiangSu Qyuns Therapeutics Co Ltd, 2022
- Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Johnson & Johnson, 2022
- Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Livzon Pharmaceutical Group Co Ltd, 2022
- Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Luye Pharma Group Ltd, 2022
- Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Lynk Pharmaceutical Hangzhou Co Ltd, 2022
- Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Mabpharm Ltd, 2022
- Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by MoonLake Immunotherapeutics, 2022
- Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Mycenax Biotech Inc, 2022
- Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by NeuClone Pty Ltd, 2022
- Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Nimbus Therapeutics LLC, 2022
- Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by North China Pharmaceutical Group New Drug Research and Development Co Ltd, 2022
- Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Novartis AG, 2022
- Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Outlook Therapeutics Inc, 2022
- Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Pharmapraxis, 2022
- Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by PKU V-Ming (Hefei) Biologics Co Ltd, 2022
- Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Qilu Pharmaceutical Co Ltd, 2022
- Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Sandoz International GmbH, 2022
- Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Shandong Danhong Pharmaceutical Co Ltd, 2022
- Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Shanghai Junshi Bioscience Co Ltd, 2022
- Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Shanghai Novamab Biopharmaceuticals Co Ltd, 2022
- Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Siam Bioscience Co Ltd, 2022
- Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by SinoCelltech Group Ltd, 2022
- Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by siRNAgen Therapeutics Corp, 2022
- Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Suzhou Zelgen Biopharmaceutical Co Ltd, 2022
- Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Tianjin Hemay Pharmaceutical Co Ltd, 2022
- Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by UCB SA, 2022
- Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Valin Technologies Ltd, 2022
- Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Wuhan Institute of Biological Products Co Ltd, 2022
- Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by XinThera Inc, 2022
- Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Zhejiang Yatai Pharmaceutical Co Ltd, 2022
- Ankylosing Spondylitis (Bekhterev's Disease) - Dormant Projects, 2022
- Ankylosing Spondylitis (Bekhterev's Disease) - Discontinued Products, 2022
- Number of Products under Development for Ankylosing Spondylitis (Bekhterev's Disease), 2022
- Number of Products under Development by Companies, 2022
- Number of Products by Top 10 Targets, 2022
- Number of Products by Stage and Top 10 Targets, 2022
- Number of Products by Top 10 Mechanism of Actions, 2022
- Number of Products by Stage and Top 10 Mechanism of Actions, 2022
- Number of Products by Top 10 Routes of Administration, 2022
- Number of Products by Stage and Top 10 Routes of Administration, 2022
- Number of Products by Top 10 Molecule Types, 2022
- Number of Products by Stage and Top 10 Molecule Types, 2022
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- 3SBio Inc
- AbbVie Inc
- Akeso Inc
- AstraZeneca Plc
- Avesthagen Ltd
- Beijing Eastern Biotech Co Ltd
- Bio-Thera Solutions Ltd
- Biocad
- Biogen Inc
- Bioviz Technologies Pvt Ltd
- BioXpress Therapeutics SA
- Boehringer Ingelheim International GmbH
- Bristol-Myers Squibb Co
- Celltrion Inc
- Clover Biopharmaceuticals Ltd
- DNX Biopharmaceuticals Inc
- Dyadic International Inc
- Eli Lilly and Co
- Enzene Biosciences Ltd
- Foshan Rexie Biotechnology Co Ltd
- FunPep Co Ltd
- Huabo Biopharm (Shanghai) Co Ltd
- Hualan Biological Engineering Inc
- Iltoo Pharma
- Immunwork Inc
- Izana Bioscience Ltd
- Jiangsu Carephar Pharmaceutical Co Ltd
- Jiangsu Hengrui Medicine Co Ltd
- JiangSu Qyuns Therapeutics Co Ltd
- Johnson & Johnson
- Livzon Pharmaceutical Group Co Ltd
- Luye Pharma Group Ltd
- Lynk Pharmaceutical Hangzhou Co Ltd
- Mabpharm Ltd
- MoonLake Immunotherapeutics
- Mycenax Biotech Inc
- NeuClone Pty Ltd
- Nimbus Therapeutics LLC
- North China Pharmaceutical Group New Drug Research and Development Co Ltd
- Novartis AG
- Outlook Therapeutics Inc
- Pharmapraxis
- PKU V-Ming (Hefei) Biologics Co Ltd
- Qilu Pharmaceutical Co Ltd
- Sandoz International GmbH
- Shandong Danhong Pharmaceutical Co Ltd
- Shanghai Junshi Bioscience Co Ltd
- Shanghai Novamab Biopharmaceuticals Co Ltd
- Siam Bioscience Co Ltd
- SinoCelltech Group Ltd
- siRNAgen Therapeutics Corp
- Suzhou Zelgen Biopharmaceutical Co Ltd
- Tianjin Hemay Pharmaceutical Co Ltd
- UCB SA
- Valin Technologies Ltd
- Wuhan Institute of Biological Products Co Ltd
- XinThera Inc
- Zhejiang Yatai Pharmaceutical Co Ltd
